Trial

NCT06771921

A First-in-Human Trial of Safety and Efficacy of GEN1078 in Participants With Solid Tumors
Phase ITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
Genmab
Collaborators
Condition
Malignant Solid Tumor
Intervention
GEN1078
Why stopped
The sponsor has made the decision to terminate further development of GEN1078 based on emerging safety observations and overall benefit-risk assessment of 1078
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-01-30